
Amphastar Pharmaceuticals AMPH
$ 29.04
4.69%
Quarterly report 2025-Q3
added 11-06-2025
Amphastar Pharmaceuticals Operating Cycle 2011-2026 | AMPH
Annual Operating Cycle Amphastar Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 195 | 188 | 205 | 206 | 241 | 264 | 199 | 219 | 231 | 197 | 229 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 264 | 188 | 216 |
Quarterly Operating Cycle Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 251 | 268 | 257 | - | 194 | - | - | - | - | - | 205 | - | 104 | 204 | 190 | - | 208 | 229 | 216 | - | 260 | 238 | 258 | 49.7 | 276 | 268 | 224 | 53.1 | 200 | 208 | 215 | 54.4 | 212 | 201 | 244 | 38.5 | 237 | 236 | 245 | 39.4 | 187 | 215 | 205 | 37.3 | 192 | 263 | 255 | 40.9 | 201 | 109 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 276 | 37.3 | 190 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adagene
ADAG
|
53.8 | $ 1.7 | 11.11 % | $ 95.7 M | ||
|
AstraZeneca PLC
AZN
|
206 | $ 95.05 | 0.42 % | $ 96.9 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Biogen
BIIB
|
452 | $ 183.04 | -2.44 % | $ 26.7 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Corcept Therapeutics Incorporated
CORT
|
364 | $ 37.6 | 0.25 % | $ 3.88 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
137 | $ 22.6 | -0.53 % | $ 2.68 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
2 K | $ 55.0 | 3.28 % | $ 4.44 B | ||
|
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 54.77 | 1.73 % | $ 4.62 B | ||
|
Catalyst Biosciences
CBIO
|
410 | $ 10.78 | -0.14 % | $ 710 M | ||
|
Cytokinetics, Incorporated
CYTK
|
177 | $ 60.85 | -2.66 % | $ 6.81 M | ||
|
DBV Technologies S.A.
DBVT
|
71.3 | $ 17.69 | 4.0 % | $ 1.72 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Celldex Therapeutics
CLDX
|
86.5 | $ 25.84 | -5.62 % | $ 1.66 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Cellectis S.A.
CLLS
|
136 | $ 4.2 | -4.76 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Enanta Pharmaceuticals
ENTA
|
37.8 | $ 12.63 | -3.66 % | $ 269 K | ||
|
Evogene Ltd.
EVGN
|
30 | $ 1.1 | -1.0 % | $ 27.9 M | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 63.42 | -1.77 % | $ 8.48 B | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Amicus Therapeutics
FOLD
|
680 | $ 14.29 | 0.04 % | $ 4.35 B |